Generation Bio Company (GBIO) Options

GBIO...................................https://stockcharts.com/h-sc/ui?s=GBIO&p=W&b=5&g=0&id=p86431144783

Welcome to Oct 2023. Buy the dip

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering price of $19.00 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,578,947 additional shares of common stock at the initial public offering price, less the underwriting discount and commissions. All of the shares are being offered by Generation Bio.
Generation Bio has been approved for listing on the Nasdaq Global Select Market and is expected to begin trading on Friday, June 12, 2020 under the ticker symbol “GBIO.” The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Generation Bio, are expected to be approximately $200 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on Tuesday, June 16, 2020, subject to customary closing conditions.

Generation Bio Co. is a genetic medicines company. The Company is developing a class of gene therapy utilizing its non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. The Company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The Company is developing gene therapies to provide targeted delivery of genetic payloads that include multiple genes to a range of tissues of diseases. The Company is also engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The Company is a preclinical stage company and have not identified a product candidate.